Head-To-Head Analysis: Moderna (NASDAQ:MRNA) and Oramed Pharmaceuticals (NASDAQ:ORMP)

Moderna (NASDAQ:MRNA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Moderna and Oramed Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94 billion	45.35	-$2.82 billion	($7.99)	-27.64
Oramed Pharmaceuticals	$2.00 million	83.20	$64.05 million	$4.12	0.97

Oramed Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.3% of Moderna shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Moderna and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Analyst Ratings

This is a summary of current ratings and recommmendations for Moderna and Oramed Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4	15	6	0	2.08
Oramed Pharmaceuticals	0	0	1	0	3.00

Moderna presently has a consensus target price of $107.10, suggesting a potential downside of 51.50%. Given Moderna’s higher probable upside, equities research analysts plainly believe Moderna is more favorable than Oramed Pharmaceuticals.

Risk & Volatility

Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Summary

Oramed Pharmaceuticals beats Moderna on 10 of the 14 factors compared between the two stocks.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.